Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
21 Pirtobrutinib Trials Near You
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerThe purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Richter's Transformation, CNS Involvement, Cardiovascular Disease, Others
Must Not Be Taking:Warfarin, Vitamin K Antagonists
725 Participants Needed
Pirtobrutinib + VR for Chronic Lymphocytic Leukemia
Columbus, Ohio
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Richter's Transformation, CNS Involvement, HIV, Others
Must Not Be Taking:Warfarin, Strong CYP3A4 Inhibitors
600 Participants Needed
Pirtobrutinib for Lymphoma
Columbus, Ohio
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Phase 1b Cohort
279 Participants Needed
Pirtobrutinib for Lymphoma
Columbus, Ohio
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Others
279 Participants Needed
Pirtobrutinib + Rituximab for Marginal Zone Lymphoma
Columbus, Ohio
The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:HIV, Active Hepatitis B, Others
Must Not Be Taking:Anticoagulants, Live-virus Vaccines
23 Participants Needed
Pirtobrutinib for Chronic Lymphocytic Leukemia
Columbus, Ohio
To assess the efficacy and safety of pirtobrutinib in participants with CLL/SLL who have progressed on first-line treatment with acalabrutinib.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Significant Cardiovascular Disease, HIV, Others
Must Be Taking:Acalabrutinib
60 Participants Needed
Pirtobrutinib for Chronic Lymphocytic Leukemia
Edgewood, Kentucky
The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to last approximately 3 years.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Richter's Transformation, CNS Involvement, Others
Must Be Taking:Covalent BTK Inhibitors
249 Participants Needed
LOXO-338 for Blood Cancers
Indianapolis, Indiana
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:CNS Involvement, HIV, Hepatitis B/C, Others
Must Not Be Taking:CYP3A4 Inhibitors, Antifungals, P-gp Inhibitors, Others
316 Participants Needed
Pirtobrutinib vs BR for Leukemia
Grosse Pointe Woods, Michigan
This trial compares a new drug, Pirtobrutinib, with an existing treatment, BR, in patients with CLL/SLL who have not been treated before. Pirtobrutinib works by blocking a protein that helps cancer cells grow, while BR damages cancer cells and helps the immune system destroy them.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Richter's Transformation, 17p Deletion, HIV, Others
Must Not Be Taking:Warfarin, Vitamin K Antagonists
250 Participants Needed
Pirtobrutinib for Immune Thrombocytopenic Purpura
Washington, District of Columbia
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo.
The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it.
The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Thrombotic Events, Cardiovascular Disease, Hematologic Malignancy, Hepatitis B, Others
58 Participants Needed
LV20.19 CAR T-Cells + Pirtobrutinib for Lymphoma
Milwaukee, Wisconsin
This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Hepatitis, Autoimmune Disease, CNS Involvement, Others
Must Be Taking:Rituximab
12 Participants Needed
Pirtobrutinib + Venetoclax for Chronic Lymphocytic Leukemia
Rochester, Minnesota
This phase II trial studies how well pirtobrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study also seeks to adopt a blood test which shows a small number of cancer cells in the body after cancer treatment called minimal residual disease as a guide to determine length of treatment. Drugs used in chemotherapy, such as pirtobrutinib and venetoclax, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Identifying minimal residual disease results after combination chemotherapy may help guide future treatment decisions for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Richter Transformation, CNS Involvement, HIV, Others
Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers, PgP Inhibitors, Vitamin K Antagonists
72 Participants Needed
Pirtobrutinib + Obinutuzumab for Chronic Lymphocytic Leukemia
Boston, Massachusetts
This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Richter's Transformation, Cardiovascular Disease, Others
Must Not Be Taking:Antiretrovirals, Immunosuppressants
60 Participants Needed
Pirtobrutinib + Venetoclax for Waldenström Macroglobulinemia
Boston, Massachusetts
This trial is testing the safety and effectiveness of two drugs, pirtobrutinib and venetoclax, in patients with Waldenström Macroglobulinemia (WM) who have already been treated but still have symptoms. Pirtobrutinib blocks a protein that helps cancer cells grow, while venetoclax blocks a protein that helps them survive. The goal is to see if this combination can better control the disease.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Lymphoma, HIV, Hepatitis, Others
Must Not Be Taking:Warfarin, CYP3A4 Inhibitors
42 Participants Needed
This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cardiac Disease, Active Infection, HIV, Others
Must Not Be Taking:Steroids, Immunosuppressants
60 Participants Needed
To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Richter's Syndrome, CNS Involvement, Others
Must Not Be Taking:Warfarin, Vitamin K Antagonists
40 Participants Needed
PRV Combination Therapy for Mantle Cell Lymphoma
Houston, Texas
Primary Objectives:
To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Involvement, HIV, Hepatitis B, Others
Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers, P-gp Inhibitors, Anticoagulants
40 Participants Needed
Pirtobrutinib + Rituximab for Lymphoma
Houston, Texas
To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Involvement, High Risk MCL, Others
Must Not Be Taking:Warfarin, Vitamin K Antagonists
50 Participants Needed
Triple Therapy for Chronic Lymphocytic Leukemia
Houston, Texas
To learn if the combination of pirtobrutinib (also called LOXO-305), venetoclax, and obinutuzumab is safe and effective when given to patients with chronic lymphocytic leukemia (CLL) or Richter transformation (RT) who have not previously received treatment.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
Must Not Be Taking:Warfarin, Strong CYP3A4 Inhibitors
60 Participants Needed
Pirtobrutinib + Venetoclax for Mantle Cell Lymphoma
Houston, Texas
This trial is testing two drugs, pirtobrutinib and venetoclax, to treat patients with mantle cell lymphoma that has come back or not responded to other treatments. Pirtobrutinib stops cancer cells from growing, while venetoclax makes them die. Venetoclax has been previously studied in children with recurring or resistant cancers and in combination with other drugs for mantle cell lymphoma.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Involvement, Stroke, HIV, Others
Must Not Be Taking:Strong CYP3A4 Inhibitors
30 Participants Needed
Why Other Patients Applied
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
To learn if the combination of LOXO-305 (pirtobrutinib) and venetoclax can help to control previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Richter's Transformation, CNS Involvement, Others
Must Be Taking:Venetoclax
44 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest clinical trials ?
Most recently, we added Pirtobrutinib + Venetoclax + Obinutuzumab for Chronic Lymphocytic Leukemia, Pirtobrutinib for Immune Thrombocytopenic Purpura and Pirtobrutinib for Chronic Lymphocytic Leukemia to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.